3 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 5.3% per year over the past 2 years.
Net income has grown faster than revenue (13.8% vs -5.3% per year).
Operating margin has expanded, at 38.9% in the latest year.
Free cash flow has declined 25.7% per year over the past 2 years.
Financial health
The company holds more cash ($164M) than total debt ($43M).
Total debt has grown faster than revenue (549.0% vs -5.3% per year).
Operating income covered interest expense 455× in the latest year, down from 1560× 2 years ago.
Total debt is 0.6× EBITDA.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$174M
$51M
73.3%
38.9%
$23M
$43M
$164M
2024
$205M
$47M
76.0%
34.2%
$18M
$7M
$125M
2023
$194M
$39M
70.9%
36.5%
$42M
—
$103M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$43M
$11M
70.5%
41.2%
$9M
$40M
$167M
Dec '25
$40M
$14M
73.1%
32.5%
$51M
$43M
$164M
Sep '25
$43M
$13M
70.6%
36.6%
-$21M
$21M
$127M
Jun '25
$43M
$2M
69.2%
33.6%
-$9M
$7M
$153M
Mar '25
$47M
$22M
79.7%
51.1%
$2M
$7M
$132M
Dec '24
$44M
$7M
76.3%
10.6%
-$8M
$7M
$125M
Sep '24
$53M
$3M
81.5%
26.1%
$5M
$823153
$137M
Jun '24
$53M
$18M
74.2%
51.4%
$18M
—
—
Mar '24
$55M
$19M
72.1%
44.6%
$3M
—
—
Dec '23
$62M
$14M
69.6%
38.5%
$22M
—
$103M
Sep '23
$47M
$8M
70.9%
42.4%
—
—
—
Jun '23
—
$196786
—
—
—
—
—
Mar '23
—
$613333
—
—
—
—
—
Dec '22
—
$565852
—
—
—
—
$485564
Sep '22
—
-$11419
—
—
—
—
$579970
Jun '22
—
-$1620
—
—
—
—
$179429
Valuation over time
How the market has priced SBC against its own fundamentals since 2024-09 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 20.5× (Sep '24) to 6.4× (Jun '26).
The price-to-sales ratio has fallen from 4.2× (Sep '24) to 1.9× (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is SBC growing its revenue and profit?
Over the past 2 years, SBC Medical Group Holdings Inc's revenue has declined 5.3% per year, and net income grown 13.8% per year. These are computed facts, not advice.
How much debt does SBC have?
As of FY2025, SBC Medical Group Holdings Inc reported $43M of total debt against $164M of cash; operating income covered interest expense 455×.
What is SBC's profit margin?
In FY2025, gross margin was 73.3%, operating margin 38.9%, and net margin 29.4%.
What is SBC's P/E ratio?
As of Jun '26, SBC Medical Group Holdings Inc traded at a price-to-earnings ratio of about 6.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.